Outcome of Botulinum Toxin Treatment for Oromandibular Dystonia (rétroBODOM)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient suffering from oromandibular dystonia
- Medical follow up in the Fondation Ophtalmologique Rothschild (Paris)
- Treatment by at least one session of botulinum toxin injection
Exclusion Criteria:
- Patient cannot assess symptoms improvement using a Likert scale
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical improvement score
Time Frame: Two months
|
Likert scale for the assessment of the clinical improvement after treatment
|
Two months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Movement Disorders
- Dyskinesias
- Dystonia
- Dystonic Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Botulinum Toxins
Other Study ID Numbers
Other Study ID Numbers
- CE_20150630_7_LSM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dystonia; Orofacial
-
NCT03428009RecruitingDystonia | Dystonia; Idiopathic | Dystonia, Primary | Dystonia, Secondary | Dystonia, Familial | Dystonia Disorder | Dystonias, Sporadic | Dystonia; Orofacial | Dystonia Lenticularis | Dystonia, Paroxysmal
-
NCT05678153Not yet recruitingSmoking | Orofacial Dysfunction
-
NCT07168850RecruitingDystonia, Focal | Limb Dystonia | Idiopathic Dystonia | Medication-refractory Dystonia
-
NCT05671068CompletedMyoclonus-Dystonia | DYT11
-
NCT02894359CompletedCervical Dystonia, Primary
-
NCT06880094RecruitingNext Generation Sequencing (NGS) | Optical Genome Mapping | Orofacial Clefts
-
NCT02877836TerminatedSpasticity | Isolated Cervical Dystonia | Complex Dystonia
-
NCT01981772CompletedOrofacial Swelling
Clinical Trials on Botulinum Toxins
-
NCT07624877Not yet recruitingChronic Pain | Neuroma | Combat Trauma | Botulinium Toxin-A
-
NCT07561580RecruitingPrimary Frontal Hyperhidrosis
-
NCT07545200CompletedBruxism | Myofascial Pain | Masseter Muscle Hypertrophy
-
NCT07295288Not yet recruiting
-
NCT07622004Completed
-
NCT07489430Not yet recruitingBlepharospasm | Blepharospasm, Benign Essential | Blepharospasm of Left Eyelid | Blepharospasm of Right Eyelid | Blepharospasm of Both Eyelids
-
NCT07526870CompletedFacial Aging | Facial Wrinkles and Rhytides Reduction
-
NCT07470164Not yet recruiting
-
NCT07236632Not yet recruiting